A Promising Innovative Medicine (PIM) designation is an early indication that leniolisib is a candidate for the MHRA's Early Access to Medicines Scheme
Terran to advance the development of two of Sanofi's Phase 3 CNS therapeutics
With the commercialization of Qvella technology for Positive Blood Culture (PBC) processing, healthcare facilities can now get results up to 24 hours faster than current methods
Flutura to deploy Cerebra Digital Twin & Pharmacologist Workbench, a self-service AI platform to accelerate impact on Pharmaceutical outcomes
Bringing together Bristol Myers Squibb and Celgene on one clinical trial management system, company goes live with Vault CTMS in record speed
New kit enhances menu of FFPE solutions and allows oncology researchers to extract higher yields of concentrated DNA compared to traditional techniques
This partnership allows both companies to become first movers to bridge an inevitable gap with the largest organizations in the pharmaceutical, nutraceutical, cosmetic, and veterinary sectors
An RMAT confers eligibility for accelerated approval and priority review of biologics licensing applications (BLA)
Cedars-Sinai Medical Center Surgeon and Surgical Innovation Officer Dr. Jain joins the venture fund to bring clinical expertise to a portfolio of budding seed-stage healthcare companies
GRC 54276 has shown tumour cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology
Subscribe To Our Newsletter & Stay Updated
